Liver Protective Effects of Renin-Angiotensin System Inhibition Have No Survival Benefits in Hepatocellular Carcinoma Induced By Repetitive Administration of Diethylnitrosamine in Mice | Zendy

Sameh Saber | Zendy; Amr A. A. Mahmoud | Zendy; Noha Helal | Zendy; Eman ElAhwany | Zendy; Rasha H. AbdelGhany | Zendy

Open Access

Liver Protective Effects of Renin-Angiotensin System Inhibition Have No Survival Benefits in Hepatocellular Carcinoma Induced By Repetitive Administration of Diethylnitrosamine in Mice

Author(s) -

Sameh Saber,

Amr A. A. Mahmoud,

Noha Helal,

Eman ElAhwany,

Rasha H. AbdelGhany

Publication year - 2018

Publication title -

open access macedonian journal of medical sciences

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.288

H-Index - 17

ISSN - 1857-9655

DOI - 10.3889/oamjms.2018.167

Subject(s) - medicine , losartan , hepatocellular carcinoma , sorafenib , angiotensin ii , renin–angiotensin system , angiotensin ii receptor type 1 , pharmacology , endocrinology , liver cancer , receptor , blood pressure

Preclinical studies have demonstrated that renin-angiotensin system (RAS) signalling has strong tumour-promoting effects and RAS inhibition was associated with improvement in the overall survival in some cancer types including hepatocellular carcinoma (HCC).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research